Cipla Limited said through its North America CEO Mark Falkin that it attended CPHI Milan to strengthen partnerships across generics, specialty, oncology, respiratory and biosimilars, including an exclusive partnership with China's Qilu Pharmaceutical to license and commercialise QL2107, a biosimilar to pembrolizumab, in the US, alongside USFDA approvals for generic Advair Diskus and the first AB-rated generic of Ventolin HFA.

Cipla shares fell 0.96% to Rs 1,314.50 after the Supreme Court directed the Centre to constitute a committee to examine measures to prevent pharma companies from offering expensive gifts and incentives to doctors.